Therapeutic Response Statement (Sensitivity)

This therapeutic response statement Supports the relationship that EGFR activating variants status confers therapeutic sensitivity to Osimertinib in patients with Non-Small Cell Lung Cancer.

The Republic of Ireland's Health Service Executive (HSE) has approved osimertinib for reimbursement as a monotherapy treatment option as a first-line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations.

This statement is based on a regulatory approval from the Health Service Executive:

First-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations.

Citation

Osimertinib Monotherapy, 2024, version number 5, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6914/353_V5_Osimertinib_Monotherapy.pdf

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2020-10-01	Health Service Executive	Indication approved for reimbursement.